WCN23-1126 ATRASENTAN FOR THE TREATMENT OF IGA NEPHROPATHY: INTERIM RESULTS OF THE AFFINITY STUDY

Endothelin A (ETA) receptor activation drives proteinuria, inflammation, and fibrosis in patients with glomerular diseases. Atrasentan, a potent and selective ETA receptor antagonist, represents a potential therapy to reduce proteinuria and preserve kidney function in patients with IgA nephropathy (IgAN) and other glomerular diseases. AFFINITY is a global, phase 2, open-label basket study to evaluate the efficacy and safety of atrasentan in adult patients with IgAN, Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney disease.